by Deana Mndrucic | Jan 27, 2021 | News
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Chief Strategy Officer, Omair Ahmed, joined nine BioForward member organizations in a discussion regarding the Wisconsin biohealth industry’s response to the COVID-19 pandemic. “We pride ourselves in... 
by Deana Mndrucic | Dec 21, 2020 | News
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers... 
by Deana Mndrucic | Dec 3, 2020 | News
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE). The diversity-based certifications, appointed by the National Minority Supplier... 
by Deana Mndrucic | Dec 2, 2020 | News
LINCOLNSHIRE, Ill.–Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for a second consecutive year. For the second year in a row, at least 76% of Nexus employees have attested that the... 
by Alicen Baran | Oct 29, 2020 | News, Product Approvals
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.... 
by Diana Lebiecki | Jun 15, 2020 | News
The Great Place to Work® Institute has honored Nexus Pharmaceuticals as one of the 2020 Best Workplaces in Chicago. The ranking considered over 27,000 responses from Chicago area employees. Great Place to Work, a global people analytics and consulting firm, evaluated... 